Skip to main content
Erschienen in: Hepatology International 1/2018

12.01.2018 | Original Article

Pathogenesis of non-alcoholic fatty liver disease mediated by YAP

verfasst von: Ping Chen, Qihui Luo, Chao Huang, Qi Gao, Like Li, Jingfei Chen, Bing Chen, Wentao Liu, Wen Zeng, Zhengli Chen

Erschienen in: Hepatology International | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Objective

This study aimed to investigate the mechanism of the interaction between Yes-associated protein (YAP) and transforming growth factor-β (TGF-β)/Smad signaling pathways in the development of non-alcoholic fatty liver disease (NAFLD).

Methods

Serum samples of monkeys with biopsy-proven NAFLD and healthy normal monkeys were used to measure fasting plasma glucose (FPG), low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglyceride (TG) and albumin (ALB) with the BECKMAN CX5 PRO. Hematoxylin-eosin staining (H&E) was used for pathologic analysis, Masson trichrome staining was used to assess for fibrosis staging, and Oil Red O staining was used to detect lipid droplet deposition. According to an NAFLD activity score of < 4 points and > 4 points, the samples were divided into groups: the steatosis group and fibrosing NASH group. Furthermore, monkeys with a fibrosis stage < 2 were assigned to the mild fibrosis group, while monkeys with fibrosis stage ≥ 2 were assigned to the significant fibrosis group. Moreover, the fibrosis stage was subdivided as follows: stages 1a, 1c and 2–3. Immunohistochemistry and real-time quantitative PCR were used to quantify protein and gene expression, respectively.

Results

In the present study, 54 monkeys with NAFLD and 23 normal monkeys were recruited. Serum FPG and TG levels were higher in fibrosing NASH monkeys compared with simple steatosis and normal monkeys, and differences between simple steatosis and normal monkeys were not statistically significant (p > 0.05). YAP increased in NAFLD, which mainly localized in the nuclei of hepatocytes, perivascular cells and bile duct cells; the accumulation of YAP correlated with the severity of hepatocyte injury. Compared with normal monkeys, the expression of TGF-β, α-smooth muscle actin (α-SMA), Drosophila mothers against decapentaplegic protein 3 (Smad3) and connective tissue growth factor (CTGF) in the liver of simple steatosis monkeys significantly increased (p < 0.01). Compared with simple steatosis monkeys, the expression of TGF-β, α-SMA, Smad3 and CTGF in fibrosing NASH significantly increased (p < 0.01). However, the expression of Drosophila mothers against decapentaplegic protein 7 (Smad7) in the liver of fibrosing NASH monkeys significantly decreased (p < 0.01). With the severity of liver fibrosis, the expression of TGF-β, α-SMA, Smad3 and CTGF gradually increased, and the difference was statistically significant (p < 0.01). However, there was no significant difference in the expression of Smad3 between fibrosis stage 1a and 1c. Compared with normal monkeys, the expression of Smad7 in the liver of monkeys with fibrosis significantly decreased (p < 0.01), but was significantly higher at fibrosis stage 1c than at fibrosis stage 1a and 2.

Conclusion

The YAP and TGF-β signaling pathways and the interaction between them promote the development and progression of NAFLD.
Literatur
1.
Zurück zum Zitat Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol 2012;107:811–826CrossRefPubMed Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol 2012;107:811–826CrossRefPubMed
2.
Zurück zum Zitat Vos MB, Barve S, Joshi BS, Carew JD, Whitington PF, McClain CJ. Cytokeratin 18, a marker of cell death, is increased in children with suspected nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2008;47:481–485CrossRefPubMedPubMedCentral Vos MB, Barve S, Joshi BS, Carew JD, Whitington PF, McClain CJ. Cytokeratin 18, a marker of cell death, is increased in children with suspected nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2008;47:481–485CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Adams LA, Lymp JF, Sauver JS, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology (Orlando) 2005;129:113–121CrossRef Adams LA, Lymp JF, Sauver JS, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology (Orlando) 2005;129:113–121CrossRef
4.
Zurück zum Zitat Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006;40:5–10 Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006;40:5–10
5.
Zurück zum Zitat Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of non-alcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence and outcomes. Hepatology 2016;64:73–84CrossRefPubMed Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of non-alcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence and outcomes. Hepatology 2016;64:73–84CrossRefPubMed
6.
Zurück zum Zitat Mederacke I, Hsu CC, Troeger JS, Huebener P, Mu X, Dapito DH, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun 2013;4:2823CrossRefPubMedPubMedCentral Mederacke I, Hsu CC, Troeger JS, Huebener P, Mu X, Dapito DH, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun 2013;4:2823CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Liu F, Lagares D, Choi KM, Stopfer L, Marinković A, Vladimir V, et al. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis. Am J Physiol Lung Cell Mol Physiol 2015;308:L344–L357CrossRefPubMed Liu F, Lagares D, Choi KM, Stopfer L, Marinković A, Vladimir V, et al. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis. Am J Physiol Lung Cell Mol Physiol 2015;308:L344–L357CrossRefPubMed
8.
Zurück zum Zitat Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev Cancer 2013;13:246–57CrossRefPubMed Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev Cancer 2013;13:246–57CrossRefPubMed
9.
Zurück zum Zitat Szeto SG, Narimatsu M, Lu M, He XL, Sidiqi AM, Tolosa MF, et al. YAP/TAZ are mechanoregulators of TGF-β-Smad signaling and renal fibrogenesis. J Am Soc Nephrol 2016;27:3117–3128CrossRefPubMedPubMedCentral Szeto SG, Narimatsu M, Lu M, He XL, Sidiqi AM, Tolosa MF, et al. YAP/TAZ are mechanoregulators of TGF-β-Smad signaling and renal fibrogenesis. J Am Soc Nephrol 2016;27:3117–3128CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Richardson M, Jonsson J, Powell E, Brunt E, Neuschwander-Tetri B, Bhathal PS, et al. Progressive fibrosis in nonalcoholic steato hepatitis: association with altered regeneration and a ductular reaction. Gastroenterology 2007;133:80–90CrossRefPubMed Richardson M, Jonsson J, Powell E, Brunt E, Neuschwander-Tetri B, Bhathal PS, et al. Progressive fibrosis in nonalcoholic steato hepatitis: association with altered regeneration and a ductular reaction. Gastroenterology 2007;133:80–90CrossRefPubMed
11.
Zurück zum Zitat Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547–1554CrossRefPubMed Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547–1554CrossRefPubMed
12.
Zurück zum Zitat Kleinerl DE, Brunt EM, Natta MV, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313–1321CrossRef Kleinerl DE, Brunt EM, Natta MV, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313–1321CrossRef
13.
Zurück zum Zitat Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Jonathan C, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387–1395CrossRefPubMed Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Jonathan C, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387–1395CrossRefPubMed
14.
Zurück zum Zitat Fan JG, Zhu J, Li XJ, Chen L, Li L, Dai F, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol 2005;43:508–514CrossRefPubMed Fan JG, Zhu J, Li XJ, Chen L, Li L, Dai F, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol 2005;43:508–514CrossRefPubMed
15.
Zurück zum Zitat Hideyuki N, Seizaburo K, Jun H, Wataru K, Shunichi T, Masashi G. Prevalence of fatty liver in a general population of Okinawa, Japan. Intern Med 1988;27:142–149 Hideyuki N, Seizaburo K, Jun H, Wataru K, Shunichi T, Masashi G. Prevalence of fatty liver in a general population of Okinawa, Japan. Intern Med 1988;27:142–149
16.
Zurück zum Zitat LeBleul VS, Taduri G, O’Connell J, Teng YQ, Cooke VG, Woda C, et al. Origin and function of myofibroblasts in kidney fibrosis. Nat Med 2013;19:1047–1053CrossRef LeBleul VS, Taduri G, O’Connell J, Teng YQ, Cooke VG, Woda C, et al. Origin and function of myofibroblasts in kidney fibrosis. Nat Med 2013;19:1047–1053CrossRef
17.
Zurück zum Zitat Mannaerts I, Leite SB, Verhulst S, Claerhout S, Eysackers N, Hoorens A, et al. The Hippo pathway effector YAP controls mouse hepatic stellate cell activation. J Hepatol 2015;63:679–688CrossRefPubMed Mannaerts I, Leite SB, Verhulst S, Claerhout S, Eysackers N, Hoorens A, et al. The Hippo pathway effector YAP controls mouse hepatic stellate cell activation. J Hepatol 2015;63:679–688CrossRefPubMed
18.
Zurück zum Zitat Machado MV, Michelotti GA, Pereira TA, Xie G, Premont R, Premont R, et al. Accumulation of duct cells with activated YAP parallels fibrosis progression in non-alcoholic fatty liver disease. J Hepatol 2015;63:962–970CrossRefPubMedPubMedCentral Machado MV, Michelotti GA, Pereira TA, Xie G, Premont R, Premont R, et al. Accumulation of duct cells with activated YAP parallels fibrosis progression in non-alcoholic fatty liver disease. J Hepatol 2015;63:962–970CrossRefPubMedPubMedCentral
19.
20.
Zurück zum Zitat Li JH, Zhu HJ, Huang XR, Lai KN, Johnson RJ, Lan HY. Smad7 inhibits fibrotic effect of TGF-Beta on renal tubular epithelial cells by blocking Smad2 activation. J Am Soc Nephrol 2002;13:1464–1472CrossRefPubMed Li JH, Zhu HJ, Huang XR, Lai KN, Johnson RJ, Lan HY. Smad7 inhibits fibrotic effect of TGF-Beta on renal tubular epithelial cells by blocking Smad2 activation. J Am Soc Nephrol 2002;13:1464–1472CrossRefPubMed
21.
Zurück zum Zitat Dooley S, Hamzavi J, Breitkopf K, Wiercinska E, Said HM, Lorenzen J, et al. Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology 2003;125:178–191CrossRefPubMed Dooley S, Hamzavi J, Breitkopf K, Wiercinska E, Said HM, Lorenzen J, et al. Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology 2003;125:178–191CrossRefPubMed
22.
Zurück zum Zitat Grannas K, Arngården L, Lönn P, Mazurkiewicz M, Blokzijl A, Zieba A, et al. Crosstalk between Hippo and TGFβ: subcellular localization of YAP/TAZ/Smad complexes J Mol Biol. 2015;427:3407–3415CrossRefPubMed Grannas K, Arngården L, Lönn P, Mazurkiewicz M, Blokzijl A, Zieba A, et al. Crosstalk between Hippo and TGFβ: subcellular localization of YAP/TAZ/Smad complexes J Mol Biol. 2015;427:3407–3415CrossRefPubMed
Metadaten
Titel
Pathogenesis of non-alcoholic fatty liver disease mediated by YAP
verfasst von
Ping Chen
Qihui Luo
Chao Huang
Qi Gao
Like Li
Jingfei Chen
Bing Chen
Wentao Liu
Wen Zeng
Zhengli Chen
Publikationsdatum
12.01.2018
Verlag
Springer India
Erschienen in
Hepatology International / Ausgabe 1/2018
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-017-9841-y

Weitere Artikel der Ausgabe 1/2018

Hepatology International 1/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

CKD bei Diabetes: Neuheiten und Zukunftsaussichten

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Jeder Mensch mit Diabetes muss auf eine chronische Nierenerkrankung gescreent werden – diese neue Empfehlung spricht die KDIGO aus. Die Therapie erfolgt individuell und je nach Szenario mit verschiedenen Substanzklassen. Künftig kommt wahrscheinlich, neben RAS-Hemmung, SGLT2-Inhibition und nsMRA, eine vierte Therapiesäule hinzu.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.